365250 Gö 6976 - CAS 136194-77-9 - Calbiochem

Overview

Replacement Information

Key Specifications Table

Empirical FormulaCAS #
C₂₄H₁₈N₄O 136194-77-9

Pricing & Availability

Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
365250-1MG
Retrieving availability...
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Plastic ampoule 1 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity needs to be mulitiple of
      Upon Order Completion More Information
      You Saved ()
       
      Request Pricing
      365250-500UG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service
          Contact Customer Service

          Plastic ampoule 500 μg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewA cell-permeable, reversible, and ATP-competitive inhibitor of protein kinase C (PKC; IC50 = 7.9 nM for rat brain). Selectively inhibits Ca2+-dependent PKC α-isozyme (IC50 = 2.3 nM) and PKCβI (IC50 = 6.2 nM). Does not affect the kinase activity of the Ca2+-independent PKC δ-, ε-, and ζ-isozymes even at micromolar levels. Reported to inhibit PKCµ at higher concentrations (IC50 = 20 nM). A 500 µg/ml solution of Gö 6976 (Cat. No. 365253) in anhydrous DMSO is also available.
          Catalogue Number365250
          Brand Family Calbiochem®
          SynonymsGo 6976, 12-(2-Cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo(3,4-c)-carbazole
          References
          ReferencesGschwendt, M., et al. 1996. FEBS Lett. 392, 77.
          Wenzel-Seifert, K., et al. 1994. Biochem. Biophys. Res. Commun. 200, 1536.
          Martiny-Baron, G.M., et al. 1993. J. Biol. Chem. 268, 9194.
          Qatsha, K.A., et al. 1993. Proc. Natl. Acad. Sci. USA 90, 4674.
          Product Information
          CAS number136194-77-9
          ATP CompetitiveY
          FormOff-white solid
          Hill FormulaC₂₄H₁₈N₄O
          Chemical formulaC₂₄H₁₈N₄O
          ReversibleY
          Structure formula ImageStructure formula Image
          Quality LevelMQ100
          Applications
          Biological Information
          Primary TargetPKC
          Primary Target IC<sub>50</sub>7.9 nM against rat brain PKC; 2.3 nM, 6.2 nM against Ca2+-dependent PKC α-isozyme and PKCβI, respectively
          Purity≥95% by HPLC
          Physicochemical Information
          Cell permeableY
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Ambient Temperature Only
          Toxicity Standard Handling
          Storage +2°C to +8°C
          Protect from Light Protect from light
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 4 months at -20°C.
          Packaging Information
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          Gö 6976 - CAS 136194-77-9 - Calbiochem SDS

          Title

          Safety Data Sheet (SDS) 

          Gö 6976 - CAS 136194-77-9 - Calbiochem Certificates of Analysis

          TitleLot Number
          365250

          References

          Reference overview
          Gschwendt, M., et al. 1996. FEBS Lett. 392, 77.
          Wenzel-Seifert, K., et al. 1994. Biochem. Biophys. Res. Commun. 200, 1536.
          Martiny-Baron, G.M., et al. 1993. J. Biol. Chem. 268, 9194.
          Qatsha, K.A., et al. 1993. Proc. Natl. Acad. Sci. USA 90, 4674.

          Brochure

          Title
          PKC Pathway Poster PDF ( 676 KB )

          Citations

          Title
        • Elizabeth A. Johnson, et al. (2006) Agonist-selective mechanisms of µ-opioid receptor desensitization in human embryonic kidney 293 cells. Molecular Pharmacology 70, 676-685.
        • Ying Zhang, Mingjuan Liao and Maria L. Dufau. (2006) Phosphatidylinositol 3-kinase/protein kinase Cγ-induced phosphorylation of Sp1 and p107 repressor release have a critical role in histone deacetylase inhibitor-mediated depression of transcription of the luteinizing hormone receptor gene. Molecular and Cellular Biology 26, 6748-6761.
        • Justin C. Mason, et al. (2004) Decay-accelerating actor induction on vascular endothelium by vascular endothelial growth factor (VEGF) is mediated via a VEGF receptor-2 (VEGF-R2)- and protein kinase C-α/ε (PKCα/ε)-dependent cytoprotective signaling pathway a. Journal of Biological Chemistry 279, 41611-41618.
        • Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision08-January-2010 RFH
          SynonymsGo 6976, 12-(2-Cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo(3,4-c)-carbazole
          DescriptionA cell-permeable, reversible, and ATP-competitive inhibitor of protein kinase C (PKC; IC50 = 7.9 nM for rat brain). Selectively inhibits Ca2+-dependent PKCα-isozyme (IC50 = 2.3 nM) and PKCβI (IC50 = 6.2 nM). Does not affect the kinase activity of the Ca2+-independent PKC δ-, ε-, and ζ-isoenzymes even at micromolar levels. A potent antagonist of HIV-1 induction.
          FormOff-white solid
          CAS number136194-77-9
          Chemical formulaC₂₄H₁₈N₄O
          Structure formulaStructure formula
          Purity≥95% by HPLC
          SolubilityDMSO (5 mg/ml)
          Storage +2°C to +8°C
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 4 months at -20°C.
          Toxicity Standard Handling
          ReferencesGschwendt, M., et al. 1996. FEBS Lett. 392, 77.
          Wenzel-Seifert, K., et al. 1994. Biochem. Biophys. Res. Commun. 200, 1536.
          Martiny-Baron, G.M., et al. 1993. J. Biol. Chem. 268, 9194.
          Qatsha, K.A., et al. 1993. Proc. Natl. Acad. Sci. USA 90, 4674.
          Citation
        • Elizabeth A. Johnson, et al. (2006) Agonist-selective mechanisms of µ-opioid receptor desensitization in human embryonic kidney 293 cells. Molecular Pharmacology 70, 676-685.
        • Ying Zhang, Mingjuan Liao and Maria L. Dufau. (2006) Phosphatidylinositol 3-kinase/protein kinase Cγ-induced phosphorylation of Sp1 and p107 repressor release have a critical role in histone deacetylase inhibitor-mediated depression of transcription of the luteinizing hormone receptor gene. Molecular and Cellular Biology 26, 6748-6761.
        • Justin C. Mason, et al. (2004) Decay-accelerating actor induction on vascular endothelium by vascular endothelial growth factor (VEGF) is mediated via a VEGF receptor-2 (VEGF-R2)- and protein kinase C-α/ε (PKCα/ε)-dependent cytoprotective signaling pathway a. Journal of Biological Chemistry 279, 41611-41618.